Treatment of Parkinson's disease with amantadine and levodopa. A one-year study.
D000368:Aged; D000547:Amantadine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001808:Blood Vessels / Q000187:drug effects; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004487:Edema / Q000139:chemically induced; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D010300:Parkinson Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D010648:Phenylacetates / Q000134:cerebrospinal fluid; D010859:Pigmentation Disorders / Q000139:chemically induced; D012867:Skin / Q000098:blood supply; D014882:Water-Electrolyte Balance
D010648:Phenylacetates; D004295:Dihydroxyphenylalanine; D000547:Amantadine